Roche ’s Ocrevus receives TGA approval for RMS and PPMS treatment in Australia
The Australian Therapeutic Goods Administration (TGA) has granted approval for Roche ’s Ocrevus (ocrelizumab) for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Australia Health | Multiple Sclerosis